Evidence map›Paper›PMID 39540236›Full record

ArticleInternational health2025

Assessing the prevalence of trachoma in the East, North, Far North and Adamaoua regions of Cameroon, 2016-2022.

Emilienne Epee, Carine Fokam Tagne, Ana Bakhtiari, Sarah Boyd, Rebecca Willis, Anna J Harte, Cristina Jimenez, Clara Burgert-Brucker, Whitney Goldman, Amir B Kello and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Emilienne EpeeFaculté de médecine et des Sciences Biomédicales, Université de Yaoundé, Yaoundé, Cameroon.
Carine Fokam TagneHelen Heller International, Yaoundé, Cameroon.
Ana BakhtiariTask Force for Global Health, Atlanta, GA, USA.
Sarah BoydTask Force for Global Health, Atlanta, GA, USA.
Rebecca WillisTask Force for Global Health, Atlanta, GA, USA.
Anna J HarteClinical Research Department, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0001-7338-7654
Cristina JimenezSightsavers, Haywards Heath, UK.
Clara Burgert-BruckerRTI International, Washington, DC, USA.
Whitney GoldmanHelen Keller International, New York, NY, USA.
Amir B KelloExpanded Special Project for Elimination of NTDs, World Health Organization Regional Office for Africa, Brazzaville, Congo.
Stephanie PalmerFHI 360, Washington, DC, USA.
Patricia HouckHelen Keller International, New York, NY, USA.
Steven ReidHelen Keller International, New York, NY, USA.
Emily ToubaliHelen Keller International, New York, NY, USA.
Yaobi ZhangHelen Keller International, New York, NY, USA.
Daniel A CohnFHI 360, Washington, DC, USA.
Fatou GueyeHelen Keller International, New York, NY, USA.
Jeremiah M NgondiRTI International, Washington, DC, USA.
Ismael TetaHelen Heller International, Yaoundé, Cameroon.
Emma M Harding-EschClinical Research Department, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0002-1432-8109
Anthony W SolomonGlobal Neglected Tropical Diseases Programme, World Health Organization, Geneva, Switzerland.
Sidi M CoulibalyOrganisation pour la Prévention de la Cécité, Bamako, Mali.
Jean Claude Noah NoahCameroon National Programme for Prevention of Blindness, Yaoundé, Cameroon.
Georges Nko'ayissiMaladies Tropicales Négligées, Ministère de la Santé Publique, Yaoundé, Cameroon.
Alain Georges Etoundi MballaFaculté de médecine et des Sciences Biomédicales, Université de Yaoundé, Yaoundé, Cameroon.
André Omgbwa EballéFaculté de médecine et des Sciences Biomédicales, Université de Yaoundé, Yaoundé, Cameroon.
Assumpta BellaFaculté de médecine et des Sciences Biomédicales, Université de Yaoundé, Yaoundé, Cameroon.

Funding

FHI 360Fred Hollows FoundationHelen Keller InternationalInternational Trachoma InitiativeMMDP Project AID-OAA-A-14-00054RTI International 7200AA18CA0001United States Agency for International Development OAA-A-11-00048World Health Organization 001
6 · The paper itself

Abstract

backgroundBaseline prevalence surveys in Cameroon in 2010-2012 showed that trachoma was endemic primarily in the north of the country, with 23 evaluation units (EUs) requiring interventions against active (inflammatory) trachoma. This study presents data from prevalence surveys conducted in 2016-2022 following interventions against trachoma in the East, North, Far North and Adamaoua regions of Cameroon.

methodsEUs were created based on health district boundaries. Within each EU, clusters were selected using probability of selection proportional to population size. Participants were examined for trachomatous inflammation-follicular (TF) and trachomatous trichiasis (TT).

resultsA total of 151 800 people were examined in 45 surveys across 35 EUs. Based on the most recent survey results, TF prevalence was greater than the 5% TF elimination threshold in two EUs. Ten EUs had TT prevalence estimates greater than the 0.2% elimination threshold.

conclusionsTrachoma remains a public health problem in Cameroon. Continued interventions are needed in EUs with prevalence estimates greater than elimination thresholds, including antibiotic mass drug administration and improved access to TT surgery. Future surveys will be needed to determine when national elimination of trachoma as a public health problem has been achieved.

Indexed as

TrachomaTrichiasisAdolescentAdultAgedAnti-Bacterial AgentsCameroonChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedPrevalenceYoung AdultAnti-Bacterial AgentsCameroonprevalence surveystrachomatrichiasisTropical Data

Identifiers

PMID39540236
PMCPMC12045092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.